본문으로 건너뛰기
← 뒤로

Medullary Thyroid Cancer: Our Current Understanding of Optimum Treatment.

1/5 보강
Endocrinology and metabolism clinics of North America 📖 저널 OA 7.4% 2022: 2/8 OA 2025: 0/17 OA 2026: 0/1 OA 2022~2026 2025 Vol.54(3) p. 443-453
Retraction 확인
출처

La Greca A, Haugen B

📝 환자 설명용 한 줄

Medullary thyroid carcinoma (MTC) is a rare form of thyroid cancer that has different treatment approaches than differentiated thyroid cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA La Greca A, Haugen B (2025). Medullary Thyroid Cancer: Our Current Understanding of Optimum Treatment.. Endocrinology and metabolism clinics of North America, 54(3), 443-453. https://doi.org/10.1016/j.ecl.2025.03.013
MLA La Greca A, et al.. "Medullary Thyroid Cancer: Our Current Understanding of Optimum Treatment.." Endocrinology and metabolism clinics of North America, vol. 54, no. 3, 2025, pp. 443-453.
PMID 40716898 ↗

Abstract

Medullary thyroid carcinoma (MTC) is a rare form of thyroid cancer that has different treatment approaches than differentiated thyroid cancer. MTC can be a challenge to diagnose by ultrasound imaging and fine-needle aspiration, so it should be considered in the differential diagnosis of any atypical thyroid nodules. Preoperative and postoperative serum calcitonin levels can help guide the surgical approach and help in monitoring and imaging. Calcitonin and carcinoembryonic antigen doubling times are helpful in prognosis and imaging. Rearranged during transfection (RET)-directed kinase inhibitors have significantly improved our therapeutic options for patients requiring systemic therapy and newer RET-inhibitors are being studied in clinical trials.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반